Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NIFKP9, or nucleolar protein interacting with the FHA domain of MKI67 pseudogene 9, is a **pseudogene**—a genomic DNA sequence resembling a gene but typically non-functional due to mutations or truncations. It does not code for a functional protein and is classified as a processed or unprocessed pseudogene depending on its origin. Pseudogenes like NIFKP9 can occasionally be transcribed into RNA and may participate in the regulation of related parental genes by acting as sources of regulatory non-coding RNAs or by modulating microRNA availability, but as of current data, there is no evidence that NIFKP9 encodes a targetable protein, has clear biological functions, or is directly implicated in disease or therapeutic targeting[3][2][4]. **Note:** - NIFKP9 should not be confused with NIFK, the functional parental gene, which is involved in mitosis and cell cycle progression[1]. - As with many pseudogenes, annotation and validation are challenging due to sequence similarity with parental genes, and their biological implications, if any, are often subtle or indirect[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleolar protein interacting with the FHA domain of MKI67 pseudogene 9 (NIFKP9).